The wave of layoffs appears, a number of pharmaceutical company job changes

Pharmaceutical network May 25th , in recent days , the departure of pharmaceutical companies is frequentYesterday, Dong Agum issued a notice on the resignation of the vice president, the board of directors recently received a written resignation report submitted by Vice President MrZhou Xiangshan, due to changes in work, MrZhou Xiangshan applied to resign as vice president of the companyAfter his resignation, MrZhou Xiangshan will no longer hold any positionin in the companyin fact, in recent days, the number of departures of pharmaceutical companies has been frequentMore than 60 executives left the industry in January-March this year, according to incomplete statistics from theIn April, 18 pharmaceutical executives offered to leave the company, bringing the total number of pharmaceutical executives who left the company at the president's and above levels alone to 13the reasons for the resignation of these executives mainly include the reasons for work, personal reasons, term expiration, division of work adjustment, etcMany pharmaceutical companies have seen the departure of several executives within a monthin addition to the departure of senior executives, but also recently out of some pharmaceutical companies layoffs news, mainly its fist products become a volume procurement of winning products, lower profits to the enterprise brought new transformation pressure, so had to lay off the sales teammore than a number of pharmaceutical companies layoffs and executive departures, this is the normal result of the three silver four, or because of the outbreak caused by the helpless status quo?Chongqing Doptai Pharmaceutical Promotion Minister Zhao Jiazhen told Saibai Blue: The outbreak has had a relatively large impact, which led to many enterprises' indicators are not very good, and even said that the end of the task is difficult to complete, so leaving is also a normal phenomenonAs for the departure of senior executives, specific analysis of specific issues, in addition to the sales indicators task can not be completed pressure, there may be some policy factors, such as national collection, basic drug catalog and medical insurance catalog, which led to a lot of enterprises change in the drug pattern, but also affected the corresponding executives to stayThe founder of Beijing Dingchen Pharmaceutical Management Consulting Center Shi Lichen expressed the same view: this year's economic environment and market competition environment are not the same, many pharmaceutical executives or the original unchanged business thinking, can not adapt to the new environment, can only leave he further explained: the new crown epidemic led to the enterprise's financial pressure is very large, some enterprises' cash flow has been out of the question; in addition, the outbreak has caused some companies to have bigger problems with their marketing teams Shi Lichen gave an example, a pharmaceutical company's sales team, sales in April for more than 200,000, but the sales cost reached 1 million, input and output ratio and its unreasonable, the overall operating efficiency is very low, the enterprise is facing a lot of financial pressure, can only adjust the talent structure, layoffs 　　This year, more changes in executive departures have been greater than usual, affecting business on the one hand, but recalibrating the company's strategic direction on the other the departure of an executive from a pharmaceutical company is not good for the business, but it will affect the future strategic direction of the company Zhao Jiazhen believes that this is conducive to the future strategic development of enterprises to adjust, such as the former enterprise is to do traditional prescription drugs and policy drugs, but with the changes in the industry, products into the national collection, then the entire sector and even the entire enterprise's product pattern will change he believes: the future prescription drugs will certainly be professional and academic transformation, but we currently have a large number of homogenized drugs do not meet, so in the pain of enterprise transformation, but also led to some difficult to adapt to the transformation, business ideas solidified executives leave at the same time, mr , Mr Slichen said that once a change in decision-making executives, the appointment of new executives would certainly bring about change, similar to the "three fires" of new officials, which would have a positive impact on the company But he also raised his concerns that there are still very few people in the pharmaceutical industry who lack real lynoist thinking the departure of senior management is important, but the real "skin pain" is the company cut the entire marketing team With the national collection, the promotion of provincial collection, enterprises must reconsider the layout of research and development, marketing and product structure adjustment, at this time the fate of the entire sales team is more worthy of attention Zhao Jiazhen admitted: Many enterprises, if the into the national collection, sales have a certain degree of protection, the value of the entire marketing team will not be particularly high The future marketing methods of pharmaceutical enterprises will be relatively large changes, although sales have the most basic bottom, but in order to combat competition, but also need to do promotion, after all, the policy provides for a single national collection of drugs, but did not force this proportion must be the highest therefore, the future of national collection of drugs, still need to be promoted, but do not need the clinical team on the ground, its representative of the guest and gold value is not significant, pharmaceutical companies to do is the top-level design projects, such as the real sense of academic promotion 　　To some extent, the future changes in the pharmaceutical companies will continue for some time because the future of drug marketing model will change, personnel changes will be corresponding: first, to professionalization, promotional transformation, and second, to the Internet plus direction The drug company's previous marketing team will naturally change zhao Jiazhen, , felt that those who pay attention to research and development and academic promotion of large enterprises, will live better and better, and those homogenized more serious, especially the production of low-end chemical imitation smaller enterprises, the future survival space will be smaller and smaller; The importance of the Chinese , as long as the product has certain characteristics, the future still has a certain space for development, but must make up for its short board, such as evidence-based evidence, after listing evaluation, as well as the corresponding guidelines and paths, etc , in order to sell the pharmaceutical enterprises to a more durable, more sustainable Shi Lichen believes that many product structure has a larger problem, in order to facilitate understanding, he will be divided into three products: policy market, policy out-of-policy market and online market policy within the market is mainly sold in hospital, relying on pharmaceutical policy prescription drugs With the national health insurance control fee, the promotion of volume procurement, the fate of this kind of products in the future is price competition, enterprises should assess themselves, if the realization of home-grown raw materials, can have greater competition and price reduction space, on the positive consistency of evaluation, actively participate in the purchase of band If there is no API, in the context of price linkage there is no competitive advantage, it is better to slowly exit the market and off-policy markets such as retail , and online markets, are the niche markets that pharmaceutical companies must pay attention to, because pricing is free, not controlled by prices, pharmaceutical companies can find new profit points in general, pharmaceutical companies to find their own business ideas and product positioning, with the corresponding job changes and personnel changes, will also begin.